S&P 500 Healthcare Sector SEC Filings β October 13, 2026
Across the ten S&P 500 Healthcare filings, the dominant theme is a split between earnings-quality noise and genuine guidance strength. UnitedHealth and Johnson & Johnson both raised full-year EPS guidance, yet UNH's Q3 operating earnings were flattered by $610 million of favorable prior-period reserve development and J&J's GAAP EPS collapsed to $0.09 on a talc litigation charge, so headline numbers need to be stripped of one-offs before they are trusted. Volume and membership trends are weakening at the managed-care end: UNH revenue slipped to $112.7 billion from $113.2 billion, Optum Health revenue fell 10% YoY, and Medicare Advantage membership shrank by 935,000 since year-end 2025. Capital-structure and governance activity is heavy but largely procedural, including Humana's CenterWell joint venture restructuring that removes a WCAS put option, Medtronic's oversubscribed MiniMed exchange offer with an estimated 18.3% proration, and several board appointments at Zoetis, Merck and Danaher. Insider activity at Intuitive Surgical is limited to routine tax withholding on RSU vestings at $423.96 per share, which signals no material conviction either way. Overall the sector picture is one of guidance held or raised by the largest names, offset by reserve-driven and litigation-driven distortions that will matter for Q4 2026 comparisons.